Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma.

Blood advances·2026
Same author

Axes of biological variation in diffuse large B cell lymphoma.

Cancer cell·2026
Same author

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphoma.

British journal of haematology·2025
Same author

Novel Molecular Insights and Evolution of Less Toxic Therapeutic Strategies in Burkitt Lymphoma.

Cancers·2025
Same author

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Related Experiment Video

Updated: Mar 11, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.6K

Update on Burkitt Lymphoma.

Kieron Dunleavy1, Richard F Little2, Wyndham H Wilson1

  • 1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

Hematology/Oncology Clinics of North America
|November 28, 2016
PubMed
Summary

Advancing Burkitt lymphoma (BL) therapeutics is challenging due to rarity and toxicity. Novel agents and intermediate-intensity approaches show promise for high cure rates with better tolerability.

Keywords:
Burkitt lymphomaCCND3EndemicID3MYCRisk-adaptedSporadicTCF3

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

41.4K

Related Experiment Videos

Last Updated: Mar 11, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.6K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

41.4K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Burkitt lymphoma (BL) is a rare but highly curable hematologic malignancy.
  • Progress in BL therapeutics has been hindered by the disease's rarity and the toxicity of standard treatments.
  • Recent identification of cooperating mutations with MYC offers new therapeutic targets.

Purpose of the Study:

  • To review recent advancements in Burkitt lymphoma therapeutics.
  • To highlight the challenges posed by treatment-related toxicity.
  • To discuss the potential of novel agents and intermediate-intensity approaches.

Main Methods:

  • Review of recent scientific literature on Burkitt lymphoma.
  • Analysis of emerging mutations cooperating with MYC.
  • Evaluation of treatment-related toxicity in standard and novel approaches.

Main Results:

  • Several new mutations cooperating with MYC have been identified, enabling novel therapeutic strategies.
  • Standard BL treatments often cause severe toxicity, leading to therapy discontinuation.
  • Intermediate-intensity therapeutic approaches have demonstrated good tolerability and high cure rates across patient groups in multicenter settings.

Conclusions:

  • Novel therapeutic strategies targeting MYC-cooperating mutations are emerging for Burkitt lymphoma.
  • Minimizing treatment-related toxicity is crucial for improving patient outcomes in BL.
  • Intermediate-intensity approaches represent a promising strategy for achieving high cure rates with improved tolerability in Burkitt lymphoma.